Arax Advisory Partners’s Arcturus Therapeutics ARCT Stock Holding History

Arax Advisory Partners’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$78.7K	Buy	11,711 +11,649	+18,789%	+$91.8K	﹤0.01%	2905
2026 Q1	$479	Buy	+62	New	+$452	﹤0.01%	3417
2025 Q4	–	Sell	-301	Closed	-$5.55K	–	4097
2025 Q3	$5.55K	Buy	301 +210	+231%	+$3.37K	﹤0.01%	2839
2025 Q2	$1.18K	Buy	+91	New	+$1.08K	﹤0.01%	2724
2024 Q4	–	Sell	-443	Closed	-$10.3K	–	2449
2024 Q3	$10.3K	Hold	443	–	–	﹤0.01%	1402
2024 Q2	$10.8K	Buy	+443	New	+$13.4K	﹤0.01%	1233

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Arax Advisory Partners's ARCT Position: Q2 2026 in Review

Arax Advisory Partners increased its Arcturus Therapeutics (ARCT) stake by 18,789% in Q2 2026, buying an estimated $91.8K and bringing the position to 11,711 shares worth $78.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2905.

Arax Advisory Partners first reported a position in ARCT in Q2 2024 and has held it in 6 quarters since. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

Arax Advisory Partners held 11,711 shares of Arcturus Therapeutics worth $78.7K as of Q2 2026.
Arax Advisory Partners bought 11,649 Arcturus Therapeutics shares in Q2 2026, an estimated $91.8K.
Arcturus Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2905 holding.
Arax Advisory Partners first reported a position in Arcturus Therapeutics in Q2 2024 and has held it in 6 quarters since.
135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.